rgejman

15 ms·

91.
by rgejman 11y ago
This website almost certainly violates FDA rules on human subject experimentation because it collects data on the effect of a drug on human subjects. I would stop working on this project until you have advisors (and lawyers) who have experi
92.
by rgejman 11y ago
That's fair, but she's writing an editorial in FASEB, which is the Federation of American Societies for Experimental Biology journal :).
93.
by rgejman 11y ago
I think this is an unfair characterization of her editorial. She did not get to her position by getting mediocre papers published in good places! She is just asking authors to be honest about whether their findings are of sufficient importa
94.
by rgejman 11y ago
You probably couldn't pay them enough to get the job done faster. Any amount you could pay them would probably be insulting compared to the # of hours it takes to properly review a paper. Also, we don't really want to increase th
95.
by rgejman 11y ago
In the biomedical sciences most publications DO NOT end up on preprint servers before being peer-reviewed and accepted. Therefore most stories are "done" a year or more before they are published anywhere. Sometimes they are prese
96.
Owning your mistakes in science(elifesciences.org)
2 points by rgejman 11y ago|0 comments
97.
Passenger mutations in mouse models of disease confound studies(arstechnica.com)
2 points by rgejman 11y ago|0 comments
98.
Why This Correction Will Likely Lead to Another Painful Bear Market(thefelderreport.com)
3 points by rgejman 11y ago|0 comments
99.
by rgejman 11y ago
Unfortunately, < 40% of trials on ClinicalTrials.gov report results after completion :(. http://www.nejm.org/doi/full/10.1056/NEJMsa1409364
100.
by rgejman 11y ago
I predict that Twitter revenue will grow as iOS 9 is released. iOS 9 will cause mobile advertising to undergo a paradigm shift as app-centered advertising becomes more important than website-based advertising. This will lead to increased ad
101.
by rgejman 11y ago
"% of total reports by age" -- are you adjusting for the # of people of each age taking the drug?
102.
by rgejman 11y ago
Is there a sample chapter? It's hard to know if I want to purchase it without knowing anything about how the book is written or whether it tried to achieve its purpose.
103.
by rgejman 12y ago
No doubt GBM patients are in major need of novel therapeutic options. My major concern with this kind of a project is that the drugs may end up killing patients faster than the tumor will. For instance, some drugs are known to inhibit tumor
104.
by rgejman 12y ago
General thoughts: Cancer patients—in particular those with blood cancers—are routinely immunocompromised and put on antibiotics. Any potent effects would almost certainly have been realized by now. There are a lot of people who have made th
105.
by rgejman 12y ago
Did AppleInsider rip off your numbers? http://appleinsider.com/articles/15/01/28/by-the-numbers-app...
106.
by rgejman 12y ago
These philanthropic organizations almost always have either (a) committees made up of scientists that decide where the money should be allocated (e.g. HHMI) or (b) donate to institutions which then dole out money internally as project grant
107.
by rgejman 12y ago
The "bait" is the claim that a patent-less drug will be cheaper when it finally comes into use in the clinic than a patented drug (from your indysci campaign: "Releasing without a patent means the drugs will be cheaper and it
108.
by rgejman 12y ago
The NIH mandates that all research it funds be placed in the public domain within 1 year of publication. http://publicaccess.nih.gov/ This does not go far enough, but it is a good start. It would be better if non-published
109.
by rgejman 12y ago
There are many problems with the institutions in this country that give grants. However, crowdsourcing is not the answer. Nor is baiting people by offering them the promise of a "patent free" cancer drug. Full-term drug developmen
110.
by rgejman 12y ago
We already have crowd funding for science. We do it as a whole society when we fund the various grant-giving agencies in this country. I cannot emphasize how bad of an idea it is to take funding decisions away from professional scientists a
111.
by rgejman 12y ago
I really don't think this is a big deal. I've had the same MTA card in my wallet for over a year (and a previous one like it for a year before that). I just top it off with $50-60 a month and there's no issue. I appreciate th
112.
by rgejman 12y ago
Unfortunately, they are usually also the best equipped to find flaws in the new work. True, this is not ideal, but it's also not ideal to send a paper to less expert reviewers. All of which goes to say that pre-print publication is the
113.
by rgejman 12y ago
There are two problems, only one of which is addressed by duplication. 1. The original study may be plain wrong. Author 1 claims to describe phenomena X, author 2 can't find any evidence for X using the exact same methodology. 2. The o
114.
by rgejman 12y ago
Yes, I did. I don't think you're interpreting the results correctly. The conclusion of the paper, in summary of all the evidence, is that "Even against the background of advances in the management of obesity-related chronic d
115.
by rgejman 12y ago
This is just not true. Being overweight or obese significantly increases all cause mortality. Here's a study where they followed 527,265 people for 10 years: http://www.nejm.org/doi/full/10.1056/NEJMoa055
116.
by rgejman 12y ago
Agreed. We need to talk about these issues as a community and come up with effective strategies to prevent data contamination. We've done this for web development and the result was a panoply of tools to validate form input. Now we nee
117.
by rgejman 12y ago
Interesting. I'd love to hear the details.
118.
by rgejman 12y ago
Data cleaning/munging is a surprisingly pervasive problem in my field ('big data' cancer research). I spend a good fraction of my time hunting down bugs caused by dirty sources upstream of my scripts. One way to fix this is t
119.
For ‘Big Data’ Scientists, Hurdle to Insights Is ‘Janitor Work’(nytimes.com)
141 points by rgejman 12y ago|60 comments
120.
by rgejman 12y ago
Agreed, for now. Caveats TBD. In particular issues of access (e.g. astrocytomas, non-metastatic bladder) and identity (what does it mean to be a CTC? A known driver mutation? We know that some tissues are littered with such mutations...)

More ›